Sanofi has reported the latest data from a Phase II clinical trial of a cluster of differentiation 40 ligand (CD40L) monoclonal antibody, frexalimab, in patients with relapsing multiple sclerosis (MS).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,